Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.
Breast cancer
BREAST CANCER RESEARCHERS LOOK BEYOND GENES TO IDENTIFY MORE DRIVERS OF DISEASE DEVELOPMENT
From University Health Network
New retrospective study aims to identify mutations to better diagnose breast cancer in the future
From Canada Newswire
Join us for the inaugural Mark Ernsting Drug Discovery Memorial Lecture. The Lecture is named in honour of Dr. Mark Ernsting, who was a Senior Biomedical Engineer in the Drug Discovery Program at OICR. Dr. Ernsting passed away in December 2015. He was a brilliant and passionate scientist and a great colleague and friend. Dr. Ernsting endeavoured to improve the lives of cancer patients by developing nanomedicines designed to deliver safer and more effective drugs.
Title of talk: Chemistry towards novel mechanism-of-action (nMoA) compounds in therapeutics discovery
Speaker: Stuart L. Schreiber, PhD
Morris Loeb Professor
Director, Center for the Science of Therapeutics
Harvard University
Broad Institute of MIT and Harvard
When: September 22, 2016, 3-5 p.m.
Where: The Great Hall, Hart House, University of Toronto, 7 Hart House Circle, Toronto, Ontario M5S 3H3
More information and free registration:
https://www.eventbrite.ca/e/mark-ernsting-drug-discovery-memorial-lecture-given-by-dr-stuart-schreiber-tickets-27005851228
OICR has announced a new retrospective study that will help to identify mutations for breast cancer, increasing understanding of the disease and potentially leading to better diagnosis in the future. The study is led by Dr. John Bartlett, Director of OICR’s Transformative Pathology Program and Dr. Harriet Feilotter, Department of Pathology and Molecular Medicine, Queen’s University. We spoke to Dr. Bartlett about why this study is important for the future of breast cancer diagnosis and treatment.
Toronto (August 17, 2016) – Mr. Peter Goodhand, President of The Ontario Institute for Cancer Research (OICR), today announced a new collaborative research study in partnership with Thermo Fisher Scientific and Queen’s University to help bring more targeted diagnosis and treatment to breast cancer patients in the future.
Noncoding RNA may play a bigger role in driving prostate cancer development and progression that previously thought.
On Monday the University Health Network’s Princess Margaret Cancer Centre announced that prostate cancer researchers, funded in part by OICR, have pinpointed the key regulatory role of 45 noncoding genes in the development and progression of prostate cancer. The research was published in Nature Genetics.
DREAM Challenge
International Team Launches Community Competition to Unravel How Cancer Changes a Cell’s RNA
From Newswise
Nanotechnology
“SMART” nanoparticle called pearls a promising gem to target, treat tumours with greater precision
From University Health Network
Stand Up to Cancer
MasterCard Starts a “Priceless® Conversation” to support Stand Up To Cancer
From Stockhouse
Technology platforms are often one of the biggest enablers of high-impact research. Since it was established in 2005, OICR has invested in developing technology infrastructure, expertise and resources in diagnostic development, genomics, imaging, informatics and medicinal chemistry. These clusters consist of research and technical experts and state-of-the-art equipment.
A new DREAM Challenge was launched on June 30 focusing on the abnormal RNA molecules in cancer cells. The ICGC-TCGA DREAM SMC-RNA Challenge is an international effort designed to improve standard methods for identifying cancer-associated rearrangements in RNA sequencing (RNA-seq) data, providing new tools for cancer researchers. Improved RNA sequencing data will allow researchers to better understand cancer leading to new and better-personalized approaches to cancer treatment.
The Challenge is open to the entire research community, and anyone interested in participating is encouraged to register at https://synapse.org/SMC_RNA.
This fall, members of the cancer research community will gather for the inaugural Mark Ernsting Drug Discovery Memorial Lecture. The Lecture is named in honour of Dr. Mark Ernsting, who was a Senior Biomedical Engineer in the Drug Discovery Program at OICR. Dr. Ernsting passed away in December 2015. He was a brilliant and passionate scientist and a great colleague and friend. Dr. Ernsting endeavoured to improve the lives of cancer patients by developing nanomedicines designed to deliver more effective drugs that minimize toxicity.
Date: September 22, 2016
Time: 3-5 p.m.
Location: The Great Hall, Hart House, University of Toronto
Keynote speaker: Dr. Stuart Schreiber, Broad Institute of Harvard and MIT
(TORONTO, Canada – July 14, 2016) – International stem cell scientists, co-led in Canada by Dr. John Dick and in the Netherlands by Dr. Gerald de Haan, have discovered the switch to harness the power of cord blood and potentially increase the supply of stem cells for cancer patients needing transplantation therapy to fight their disease.
